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Background: To support antibiotic prescribing for both hospital and community-based
health professionals working in remote North Western Australia, a multidisciplinary
Antimicrobial Stewardship (AMS) Committee was established in 2013. This Committee is
usually focused on hospital-based prescribing. A troubling increase in sulfamethoxazole/
trimethoprim resistance in Staphylococcus aureus antibiograms from 9 to 18% over
1 year prompted a shift in gaze to community prescribing.
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What we did: Finding a paucity of relevant research, we first investigated contextual
factors influencing local prescribing. We also designed a systematic survey of experts
with experience relevant to our setting using a structured response survey (12 questions)
to better understand specific AMS risks. Using these findings, recommendations were
formulated for the AMS Committee.
What we learned: Prescribing recommendations in a regional Skin Infections Protocol
had previously been altered in December 2014. From 15 experts, we received 9 comprehensive responses (60%) about AMS risks in community prescribing. If feasible, prescribing audits also would have been valuable. Ten recommendations regarding specific
antibiotic recommendations were submitted to the AMS Committee.
strengthening AMs in remote settings: As AMS Committees in Australia usually focus on
hospital-based prescribing, novel methods such as external expert opinion could inform deliberations about community-based prescribing. Our approach meant that this AMS Committee
was able to intervene in the 2017 organizational review of the regional Skin Infections Protocol
used by prescribers likely unaware of AMS risks. This experience demonstrates the value of
incorporating AMS principles in community-based prescribing in context of a remote setting.
Keywords: antimicrobial stewardship, community-based prescribing, remote indigenous health, impetigo,
Streptococcus pyogenes

Abbreviations: ACCHO, Aboriginal Community Controlled Health Organisation; APSGN, acute post-streptococcal glomerulonephritis; ARF, acute rheumatic fever; AMS, antimicrobial stewardship; ca-MRSA, community-acquired methicillin-resistant Staphylococcus aureus; DDDs, daily defined doses; DOT, directly observed therapy; GAS, group A Streptococcus
pyogenes; GARP, Global Antibiotic Resistance Partnership; KSDL, Kimberley standard drug list; LAB, LA-Bicillin; MRSA,
methicillin-resistant Staphylococcal aureus; NAPS, National Antimicrobial Prescribing Survey; PK/PD, pharmacokinetic/
pharmacodynamic; RANs, remote area nurses; RHD, rheumatic heart disease; SXT, sulfamethoxazole/trimethoprim
(“co-trimoxazole”); WACHS, Western Australian Country Health Service.
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INTRODUCTION

Identification of Factors Influencing
Prescribers

Antimicrobial stewardship (AMS) is a global response to a universal imperative to promote responsible prescribing (1). Some
700,000 people die of bacterial infections resistant to effective
antibiotics every year (2). In Australia, considerable attention
has been focused on antibiotic prescribing in hospitals (3). Yet
antibiotic use in community settings in Australia is high (4, 5).
In 2014, almost half (46%) of Australians had at least one anti
microbial dispensed to them with an overall rate of 23.8 “daily
defined doses” per 1,000 inhabitants per day (4). Rates of antibiotic resistance behoove both global and local responses (6).
The Kimberley region of North Western Australia is one of
Australia’s most remote. It has a small population of approximately
40,000 people spread over an area as large as Germany. About half
of the resident population is Aboriginal (7). Health outcomes are
inequitable (7). Delivery of healthcare is challenging. Hospital
services for the Kimberley region are provided exclusively by
Western Australian Country Health Service (WACHS). While
WACHS also provides primary healthcare clinic services, it is
not the monopoly provider. Remote Aboriginal communities are
served by a mix of WACHS-managed primary healthcare services
and Aboriginal Community Controlled Health Organisation
(ACCHO).1 This plurality of primary healthcare services requires
partnership between them (8).
In 2013, WACHS created an AMS Committee for the
Kimberley region with membership from all relevant disciplines
from both WACHS and ACCHO services. Since then, it has
focused on hospital-based prescribing, particularly as tools such
as the National Antibiotic Prescribing Survey are readily available
to do so.2 In December 2015 however, antibiograms received by
the AMS Committee showed an increase across the region in
methicillin-resistant Staphylococcus aureus (MRSA) resistance to
sulfamethoxazole/trimethoprim also known as “co-trimoxazole”
(SXT) from 9% in one 12-month period (July 2013–June 2014)
to 18% in the next (July 2014–June 2015). In contrast, Australian
rates of MRSA-resistant to SXT usually range from 2.5 to 11.9%
(4). In an AMS Committee dominated by hospital members
and usually dealing with hospital prescribing, this troubling
increase in SXT resistant MRSA prompted an urgent pivot toward
community-based prescribing.

We first informally examined sources of information, regulations,
and experiences likely influencing prescribers. Skin infections
including impetigo are very common among Aboriginal people
supplied by government with housing inadequate for cultural
demands and social use. From 10 population prevalence studies
reporting data for children living in remote Aboriginal communities of northern Australia, the median prevalence of impetigo
reported from these studies was 44.5% (9). Furthermore, the organism predominantly driving impetigo is Group A Streptococcus
pyogenes (GAS) rather than Staphylococcus aureus (10). As a result
of this epidemiological picture, the aims of prescribing to treat
impetigo in the Kimberley are twofold: first, to accelerate skin
healing and, also, to prevent serious GAS sequelae such as acute
rheumatic fever and acute post-streptococcal glomerulonephritis
(APSGN).
All authorized prescribers in Australia can access national
Therapeutic Guidelines online.3 Because of the plurality of service
organizations in our region as previously described, a suite of
about 20 Kimberley-specific clinical protocols also is promoted
upon arrival in the region at staff orientation and during inservice.4 These protocols are designed to support inexperienced
health professionals unused to working in a setting as remote as
the Kimberley and also to minimize prescribing deviations outside the agreed Kimberley standard drug list (KSDL) common to
all services. We looked closely at the prescribing sections of one
of these protocols, namely the Kimberley Skin Infections Protocol.5
We sought relevant pharmacological literature, also searching
widely for community-based prescribing research conducted in
remote settings with Aboriginal people rather than mainstream
urban settings. We investigated the feasibility of a prescribing
audit in the Kimberley but found both logistics and costs prohibitive as no standard audit tools were available. In addition, we
resolved to obtain expert clinical input.

Expert Clinical Input

The AMS Committee agreed we could approach independent
experts and reviewed the names of proposed experts for disciplinary background and relevant experience working in remote
Aboriginal healthcare. Each of these then was first approached
by email by SO requesting assistance in this AMS project. Our
invitation outlined the purpose of our request and provided six
article abstracts found in our literature review (available upon
request from SO). We also attached the Kimberley antibiograms
for the period July 2014–June 2015 (Figure 1) with the link to
the current Kimberley Skin Infections Protocol. A structured
response sheet presenting a list of 12 questions with a deadline for
completion was used to guide expert review (Box 1). Development
of these specific questions came out of our initial examination, earlier informal consultations, and literature review. About 4 weeks

WHAT DID WE DO TO ENHANCE OUR
UNDERSTANDING OF PRESCRIBING
RISKS AND BENEFITS?
To assist a hospital-focused AMS Committee better understand
community-based prescribing, a working group (SO, JC, JW)
was tasked with summarizing evidence and risks of prescribing choices when treating bacterial skin conditions affecting
Aboriginal people in remote community clinics. No additional
resources were available.

https://tgldcdp.tg.org.au/etgcomplete.
http://resources.kamsc.org.au/protocols.html.
5
http://103.18.109.102/~kamscorg/wp-content/uploads/2015/04/oth-SkinInfections.pdf.
3
4

1
2

http://www.kahpf.org.au/.
https://www.naps.org.au.
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FIGURE 1 | Example of antibiogram discussed by antimicrobial stewardship Committee in December 2015.

after initial invitation, one of us (JC) made a prompting telephone
call or collegial reminder to any non-respondent to encourage
response.

and Poisons Act (2014) and regularly updated legislation, creden
tialed Remote Area Nurses (RANs). A pre-existing version of
the Kimberley Skin Infections Protocol produced originally in
2010 had flucloxacillin orally for 6 days or, if adherence to an
oral schedule would be difficult, intramuscular injection of longacting benzathine benzylpenicillin (LA Bicillin®) (LAB) for both
adults and children.
This 2010 Protocol had been revised in some haste during
2014 in the context of an outbreak of APSGN in the Kimberley
on the basis that GAS impetigo was the causative trigger. Changes
introduced during this revision had included a prescribing
recommendation to use SXT as an equivalent first-line oral
alternative to intramuscular LAB. The AMS Committee itself had
no formal record of these changes or AMS scrutiny. Released in
December 2014, this version of the Protocol had been in place for
about 1 year at the time that the AMS Committee first received
data showing increasing MRSA resistance to SXT across the

Progress Reporting to AMS Committee

Throughout the process, we prepared project updates either
verbally at meetings or in writing to the AMS Committee.
Suggestions we submitted regarding process, selection of experts,
and findings.

WHAT DID WE LEARN?
Guidelines and Other Sources of
Prescribing Directions in the Kimberley

Prescribers in the Kimberley are either medical practitioners or,
in circumscribed clinics in accordance with the WA Medicines
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One of us, JW, was charged with the task of de-identifying
and collating written responses. Extensive comments were
considered over dedicated meetings of the working group. This
process affirmed that antibiotic exposure raises risk for antibiotic resistance at individual as well as community and regional
levels. All expert survey respondents confirmed the AMS risks
and trade-offs inherent in first-line antibiotic choices in treating Aboriginal children with impetigo. These also included the
options of oral versus intramuscular routes. A direct correlation
between increasing antibiotic resistance, as observed by the locally
produced antibiograms, and increasing SXT antibiotic exposure
could not be excluded. Survey responses focused attention on a
single study conducted in the Northern Territory comparing an
oral antibiotic alternative to intramuscular LAB for the first-line
treatment of impetigo in Aboriginal children (11). As explained
by the researchers, their selection of SXT as this oral antibiotic
alternative would cover MRSA as a causative organism and their
previous in vitro study demonstrating susceptibility of GAS
to SXT. They also explained that, if S. aureus was causative of
impetigo in any given individual, then intramuscular LAB would
be insufficient (11). Survey respondents’ comments generally
agreed that impetigo within Australian Aboriginal populations is
driven by S. pyogenes (GAS). Regardless of concomitant S. aureus
carriage in skin infection, treatment of S. pyogenes alone results
in clinical resolution. In the Kimberley, clinicians must manage
high rates of GAS infections but also a wide range of clinical
manifestations of S. aureus infections, ranging from simple boils
and cellulitis to complex deep tissue and joint infections and life
threatening sepsis. Our rates of community-acquired methicillinresistant Staphylococcus aureus (ca-MRSA) are high. SXT should
remain one of the region’s most precious oral antibiotic agents for
ca-MRSA infections demonstrated to be sensitive to SXT.
Responses from our review also suggested the importance of
separately addressing community-based treatment of S. aureus
infections in any revision of the Kimberley Skin Infections
Protocol. Treatment of non-impetigo cases known or suspected
to be caused by S. aureus needed greater detail. As decided by the
AMS Committee, a separate guideline for inpatient management
will also be produced with clear links from the communitybased Protocol to a hospital-based prescribing protocol. This
hospital protocol for more severe infections requiring admission
is under-way and will be informed by a concurrent study of
diagnosis, treatment, and prescribing of impetigo in Aboriginal
children once hospitalized (13).
Expert responses also helped us as a working group to highlight specific methodological aspects of previous research. One
study showing a reduction by day seven of S. aureus carriage in
Aboriginal children with impetigo had compared one of two previously un-trialed SXT regimes against intramuscular LAB based
on non-adherence concerns (11). Specifically, the trial compared
a 3-day course of SXT at a standard dose twice daily versus a 5-day
course at a novel double-dose once-daily but, importantly, all doses
were “directly observed” (11). Also known as directly observed
therapy (DOT), such a standard for clinical treatment of patients
with impetigo in the Kimberley was discussed at length by the
working group. In addition, this trial had not assessed SXT resistance. Methods including pharmacokinetic/pharmacodynamic

BOX 1 | Twelve questions asked of experts in a structured response survey.
• Is prescribing according to the Protocol driving up multi-methicillin-resistant
Staphylococcus aureus (MRSA) rates?
• Does the option of 3-day duration of co-trimoxazole versus 5-day duration
raise risk of increasing multi-MRSA rates?
• What is the best use of co-trimoxazole in community prescribing in a region
with very high rates of cMRSA, and where it remains our most useful oral
agent for cMRSA?
• Does co-trimoxazole bring corroborated benefit in reducing initial or recurrent acute rheumatic fever as does LAB?
• Should the first-line advice given in the Protocol be changed to strongly
emphasize LAB as first line and an oral alternative as second line in very
limited situations?
• What is the role of oral penicillins and/or cephalexin as first-line prescribing
options?
• Cephalexin is prescribed as a first-line antibiotic for impetigo in non-Aboriginal patients. Should it be specified as a first-line antibiotic for community-based treatment of impetigo in the Kimberley?
• Should a revision of the protocol specify a focus on Aboriginal children
0–17 years of age rather than, as currently, no age specified?
• Should there be a regular census (audit) conducted periodically in the
Kimberley by which a large number of swabs were taken simultaneously
according to a census protocol to provide useful antiobiograms and other
AMS-related data, or can we rely on our current antiobiograms to inform
decisions?
• Is there a need to design and put in place a long-term monitoring system
for antibiotic resistance in the Kimberley? What might be a warning light
that we need to protect co-trimoxazole for use in cMRSA?
• Should a standardized concordance audit be designed to ask each clinic
or PHC service to show how a patient with a skin infection was treated and
whether according to the protocol using a standardized tool?
• Should the revised protocol alert clinicians to multiple previous presentations for skin infections as reason to refer to Environmental Health
services using EH referral form?

region. Anecdotally through emails between prescribers and
queries to pharmacists, the use of SXT as first-line oral antibiotic
for impetigo had increased over that year. A system of Standing
Orders authorized by the Director-General of WA Health listed
SXT as well as intramuscular LAB for use by RANs to treat “skin
infections.”
None of the clinical record systems used in primary healthcare
in the Kimberley could generate prescribing data linked to impetigo treatment in order to quantify actual prescribing behavior as
part of this investigation. Examining turnover of stock and trends
in SXT ordering by interrogating pharmacy imprests of each
remote clinic setting also was precluded on the basis of available
resources and, in any case, would have been far less precise.

Expert Input Adds to Published Evidence

From 15 experts and clinicians asked to provide input, we
received 9 completed response sheets (60%) providing an appro
priate diversity of disciplines including general practice, pediatric
infectious diseases, clinical microbiology, clinical phar
macy,
and experienced remote area pediatrics. Although every article
provided with our structured response survey had been utilized
by at least one respondent completing this section, crucially
one had been used by all (11). As one additional article was
cited by one respondent only (12), we were reassured that the
resources we had provided were comprehensive and sufficient for
respondents.
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(PK/PD) analyses to determine PK/PD indices to optimize
efficacy and avoid emerging resistance are needed for SXT
(14, 15). Furthermore, it is known that SXT has a shorter half-life
in children (16). As a working group so advised, we concluded
that all antibiotic dosing regimes should be conventional and,
in keeping with AMS principles and the evidence before us,
conservative in a remote setting. Indeed, we were advised that
the eTG specifies cephalexin for impetigo in non-Aboriginal
children.
Survey responses also reinforced the role of environmental
determinants of skin infections in Aboriginal children. As one
respondent suggested: “… we have to make a start in addressing
the environmental factors that are contributing to high rates of skin
infection. It does need to be part of a wider strategy addressing the
social determinants of health such as overcrowding though I accept
that this is likely to be beyond the scope of the review.” Our working
group agreed.
Readers can request from SO a full copy of the responses with
AMS Committee permission.

BOX 2 | Prescribing recommendations for community-based treatment of
impetigo in remote Australia.
First-Line ORAL Antibiotic Alternative to Benzathine Penicillin
(LA Bicillin) Depot Injection for Impetigo Treatment
• We recommend keeping the choice of an oral antibiotic alternative to
LA Bicillin for the initial treatment of impetigo.
• We recommend, as informed by local antibiograms, that this oral
alternative should no longer be sulfamethoxazole/trimethoprim (“co-trimoxazole”) (SXT) due to the concern of increasing methicillin-resistant
Staphylococcus aureus (MRSA) resistance to SXT in the region.
• We recommend instead that the oral antibiotic alternative, knowing that
impetigo is almost always driven by Streptococcus pyogenes, be a more
narrow spectrum antibiotic. Due to the current evidence base about
oral penicillins, we recommend compliance with the current Australian
Therapeutic Guidelines recommendations for impetigo in non-indigenous
children of cephalexin until more evidence is available.
• Where both penicillin and sulfur allergy are present, we recommend a
review of the current suggested alternative of roxithromycin by the maternal
and child health sub-committee. Where only penicillin allergy is present, we
recommend continuation of the current recommendation in the Protocol,
i.e., SXT, noting issues raised about SXT dosage and antibiotic resistance
(i.e., twice daily versus once-daily regimes).
• We recommend the need for thorough dialog with parents/families about
these choices for impetigo treatment so they are better informed about
the options, and are actively involved in the choice of either injection or
oral therapy.
• We recommend staff education in ways to administer LA Bicillin in a
patient friendly manner and in ways shown to significantly reduce pain
in recipients.
• We recommend no change to the advice in the guideline about the
routine use of directly observed therapy (DOT) to improve oral antibiotic
adherence, i.e., there is no need to introduce DOT as an element of
prescribing.
• We recommend impeccable follow up with all patients with impetigo to
assess success of antibiotic therapy.

Actions by the AMS Committee

Having discussed every written response and common themes,
we prepared written recommendations for the AMS Committee
in two sections: one, longer and comprising eight recommendations, addressed the first-line oral antibiotic alternative to
intramuscular LAB for impetigo in Aboriginal children and, the
second, comprising two recommendations about non-impetigo
skin infections (Box 2). In response to local contextual factors
influencing prescribing, we recommended retaining the option
for an empiric oral antibiotic alternative alongside intramuscular
LAB for the initial treatment of GAS impetigo in Aboriginal
children in remote Australia. Consistent with AMS principles,
SXT should be removed as this first-line oral alternative due to a
disturbing increase in MRSA resistance to SXT in the region. In
a setting of high (and rising) MRSA resistance to SXT, we were
confident that we could recommend that SXT should be used
selectively especially when other options were readily reaffirmed
by experts participating in our survey. Until more evidence is
available, we recommended compliance with the Australian
Therapeutic Guidelines (eTG) prescribing recommendation for
impetigo of cephalexin. Recommendations were also made about
audit, community engagement, and environmental determinants
(Box 2).
On the basis of this process and its own deliberations based
on the diverse sources of input obtained, the AMS Committee
endorsed these recommendations in October 2016 and
requested a comprehensive review of the Kimberley Skin Infec
tions Protocol. It provided a comprehensive report to the KAHPF
Maternal and Child Health SubCommittee responsible for
this review (due mid-2017) including an explanation of AMS
principles. Additional consultation will take place. As the most
recent antibiogram received by the AMS Committee from
January 2015 to December 2015 showed continuing MRSA
resistance to SXT in the Kimberley (19%), this initiative to apply
sound AMS principles to community-based prescribing was
timely. Unpublished data also made available shows that the
WA121 strain of S. aureus now accounts for half of all strains
Frontiers in Public Health | www.frontiersin.org

Non-Impetigo Skin Infections
1. We recommend that the skin infection protocol continue to be inclusive
of all skin infections, however, we recommend far greater clarity for
clinicians regarding the clinical assessment to distinguish infection driven
by Streptococcus (impetigo) versus infection driven by Staphylococcus
(boils, abscess) versus infections such as cellulitis which are likely a
combination. This is critical as treatment and potential complications are
different. Currently, the Protocol implies a blanket LA Bicillin injection or
oral co-trimoxazole for all presentations. If the patient has a staph driven
infection, LA Bicillin is inappropriate.
2. We recommend routine swabbing of any lesion(s) suspected to be
Staphylococcus driven. Even if MRSA is found to be colonizing the
wound, other bacteria may still be driving the infection and need treatment
especially in more serious infections.

of S. aureus found in the Kimberley. WA121 is routinely resistant
to SXT (17, 18).

STRENGTHENING AMS IN REMOTE
SETTINGS
This experience identifies future directions for AMS Committees
such as ours in remote settings that oversight both hospital-based
and community-based prescribing. By obtaining external expert
opinion where required in conjunction with relevant literature,
this AMS Committee has initiated an organizational review of
5
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a regional Skin Infections Protocol that is used as a resource by
prescribers likely unaware of AMS risks.
There is potential for still more strategies to strengthen AMS
in community-based antimicrobial choices such as the case study
described here. Although no methodical audits could be undertaken on this occasion to quantify prescribing practices in the
Kimberley as part of our project, audits with feedback can provide powerful signals that change prescribing behavior (19, 20).
We are hopeful that there will be committed support for such
AMS activities in the future including audits and routine reporting to the AMS Committee of drug ordering by regional pharmacies. A survey of medical and nursing prescribers would also have
shone light on their perspectives. PathWest has been encouraged
to consider inter-regional comparisons and time-series trend
analyses of SXT resistance. Certainly, clinical prescribing audits
will be needed to monitor the impact of future Protocols.
Culturally informed initiatives could better promote antibiotic adherence in our context, especially when combined with
resources proven to support decisions by Aboriginal people for
complex diseases in disadvantaged circumstances. Culturally
specific resources to explain antibiotics or antibiotic resistance
are rare in Australia (21) and non-existent in any Aboriginal language of the Kimberley. As concerns with pain may be acting as
an impediment to intramuscular LAB, staff education should also
be strengthened. Unfortunately, there are few resources available
to upskill clinicians to reduce pain from LAB as an intramuscular
injection. Rheumatic heart disease (RHD) Australia has a module
within a series on RHD that requires registration to complete.
In addition to a project in New Zealand that trialed the use of
lignocaine injection and a small vibrating bee-shaped device with
ice-pack wings placed specifically in relation to the injection site
and nerve fibers (22), an Australian pediatric service based in
Townsville serving remote communities through outpatient
visits has been trialing a child friendly method, with anecdotally
reported success.6 Others concur with the need for more patientcentered approaches to penicillin use (23). Specifically, 10 clinical
experts in RHD identified characteristics of benzathine penicillin
G formulations which could be changed to improve adherence
with secondary prophylaxis. Those overwhelmingly put forward
included dose interval, pain, and administration mechanism
(23). Looking further to the emerging ethical complexities of
managing antimicrobial risks for entire populations alongside
individual autonomy (24), we suggest that presenting communities with data about antibiotic resistance and entering into genuine
long-term discussion about these complexities will better support
strategies that re-empower and inform communities otherwise
excluded from policy formation (25).

Future guidance to clinicians should emphasize impeccable
follow-up of all patients with impetigo in order to corroborate
clinical resolution of infection and continue to reinforce the
importance of antibiotic adherence. In a population that is highly
mobile between primary healthcare providers, effective strategies will need to be developed in partnership with Aboriginal
communities themselves. Finally, the preconditions of access to
clean water, sanitation, and other enablers for personal hygiene
essential to reduce antimicrobial resistance have been powerfully argued (2). For example, the first of six national strategies
recommended by the Global Antibiotic Resistance Partnership
is to reduce the need for antibiotics by improving access to
clean water and functional sewerage systems, and ensuring a
safe and healthful food supply (1). In remote Aboriginal communities in the Kimberley, basic sanitation, water, and housing
stock including health hardware in the home have been repeat
edly shown to be substandard (26, 27). As does the World
Health Organization (28), we are convinced that these environ
mental aspects should also be a focus for local AMS Committees.
In the Kimberley, impetigo and other skin infections are
directly attributable to the environment (29). Primary healthcare services could address not only clinical prescribing for
impetigo but also local partnerships with environmental health
services to address environmental determinants and deliver
sustained environmental health promotion. AMS risks make
this a pressing priority. Forward-looking AMS Committees
should maintain the broadest awareness of the multitude of
factors that exacerbate antibiotic resistance (30).
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